
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3398358/publications.pdf

Version: 2024-02-01



#	Article	lF	CITATIONS
1	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. Journal of the American College of Cardiology, 2006, 47, 1369-1378.	1.2	168
2	Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Critical Care, 2009, 13, R158.	2.5	105
3	Hyperhomocysteinemia in Liver Cirrhosis. Hypertension, 2001, 38, 1217-1221.	1.3	97
4	Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease. Scientific Reports, 2019, 9, 15580.	1.6	91
5	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
6	Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Frontiers in Bioscience - Landmark, 2008, 13, 2916.	3.0	78
7	Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis, 2003, 171, 67-73.	0.4	64
8	Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis, 2007, 5, 91-97.	1.9	62
9	Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis, 2003, 167, 45-53.	0.4	61
10	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/Câ€X  chemokine receptor 4 axis. Hepatology, 2015, 62, 166-178.	3.6	61
11	Association of Sepsis-Related Mortality with Early Increase of TIMP-1/MMP-9 Ratio. PLoS ONE, 2014, 9, e94318.	1.1	60
12	Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thrombosis and Haemostasis, 2008, 99, 382-387.	1.8	59
13	Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitor–Mediated Mechanism. Circulation, 2011, 124, 2909-2919.	1.6	54
14	Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Critical Care, 2011, 15, R97.	2.5	53
15	Synergistic Effect of Thrombin and CD40 Ligand on Endothelial Matrix Metalloproteinase-10 Expression and Microparticle Generation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1477-1487.	1.1	53
16	Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clinica Chimica Acta, 2006, 368, 138-143.	0.5	52
17	Torasemide Inhibits Angiotensin II–Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats. Hypertension, 1999, 34, 138-143.	1.3	48
18	Vitamins C and E Reduce Retinal Oxidative Stress and Nitric Oxide Metabolites and Prevent		45

<sup>18</sup> Ultrastructural Alterations in Porcine Hypercholesterolemia. , 2005, 46, 1140.

#	Article	IF	CITATIONS
19	Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis, 2002, 165, 33-40.	0.4	44
20	Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovascular Research, 2005, 65, 665-673.	1.8	44
21	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
22	Matrix Metalloproteinase-10 Is Upregulated by Thrombin in Endothelial Cells and Increased in Patients With Enhanced Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2109-2116.	1.1	42
23	Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors. DMM Disease Models and Mechanisms, 2016, 9, 541-52.	1.2	42
24	MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy. Stem Cells, 2014, 32, 447-461.	1.4	39
25	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	2.6	37
26	The CXCR4/SDF1 Axis Improves Muscle Regeneration Through MMP-10 Activity. Stem Cells and Development, 2014, 23, 1417-1427.	1.1	36
27	A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1370-1382.	1.1	36
28	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 428-435.	0.6	35
29	Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury. PLoS ONE, 2014, 9, e94370.	1.1	34
30	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). Journal of Extracellular Vesicles, 2020, 9, 1729646.	5.5	34
31	The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Critical Care, 2013, 17, R94.	2.5	31
32	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis, 2018, 278, 124-134.	0.4	27
33	Effect of Lutein and Antioxidant Supplementation on VEGF Expression, MMP-2 Activity, and Ultrastructural Alterations in Apolipoprotein E-Deficient Mouse. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-11.	1.9	25
34	Combined sustained release of BMP2 and MMP10 accelerates bone formation and mineralization of calvaria critical size defect in mice. Drug Delivery, 2018, 25, 750-756.	2.5	25
35	Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity. Biochemical and Biophysical Research Communications, 2009, 389, 378-381.	1.0	24
36	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. Journal of the American Heart Association, 2017, 6, .	1.6	24

#	Article	IF	CITATIONS
37	MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. Scientific Reports, 2020, 10, 26.	1.6	24
38	Egg yolk improves lipid profile, lipid peroxidation and retinal abnormalities in a murine model of genetic hypercholesterolemia. Journal of Nutritional Biochemistry, 2008, 19, 40-48.	1.9	23
39	MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes. Translational Stroke Research, 2019, 10, 389-401.	2.3	21
40	Effects of cryopreservation on the immunogenicity of porcine arterial allografts in early stages of transplant vasculopathy. Cryobiology, 2005, 51, 130-141.	0.3	20
41	Functional MMPâ€10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB Journal, 2015, 29, 960-972.	0.2	19
42	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. Journal of Vascular Surgery, 2017, 66, 1527-1533.e1.	0.6	19
43	Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488.	2.9	18
44	Inner ear drug delivery through a cochlear implant: Pharmacokinetics in a Macaque experimental model. Hearing Research, 2021, 404, 108228.	0.9	18
45	Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovascular Research, 2004, 63, 176-185.	1.8	17
46	Antioxidant effects of vitamins C and E, multivitamin-mineral complex and flavonoids in a model of retinal oxidative stress: The ApoE-deficient mouse. Experimental Eye Research, 2008, 86, 470-479.	1.2	16
47	Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. Thrombosis Research, 2015, 136, 445-450.	0.8	15
48	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	1.8	15
49	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. Thrombosis Research, 2018, 170, 1-9.	0.8	12
50	Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3 <i>R</i> )-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]- <i>N</i> -methylbenzamide (CM-352), for the Prevention and Treatment of Hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957.	<sup>2)</sup> 2.9	11
51	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. BMC Neurology, 2015, 15, 111.	0.8	11
52	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. Life, 2021, 11, 414.	1.1	9
53	Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2022, 63, 648-656.	0.8	8
54	Role of Programmed Electrical Stimulation of the Heart in Risk Stratification Post-Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 283-288.	0.5	6

#	Article	IF	CITATIONS
55	Association Between Matrix Metalloproteinase-10 Concentration and Smoking in Individuals Without Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed ), 2008, 61, 1267-1273.	0.4	6
56	High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients. BMC Neurology, 2019, 19, 167.	0.8	6
57	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 327-328.	0.6	5
58	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. Journal of Critical Care, 2019, 51, 117-121.	1.0	5
59	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	1.6	5
60	Elevated circulating metalloproteinase 7 predicts recurrent cardiovascular events in patients with carotid stenosis: a prospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 93.	0.7	5
61	Molecular and Cellular Mechanisms of Delayed Fracture Healing in <i>Mmp10</i> (Stromelysin 2) Knockout Mice. Journal of Bone and Mineral Research, 2021, 36, 2203-2213.	3.1	5
62	The Bone Regeneration Capacity of BMP-2 + MMP-10 Loaded Scaffolds Depends on the Tissue Status. Pharmaceutics, 2021, 13, 979.	2.0	3
63	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. ACS Medicinal Chemistry Letters, 2018, 9, 428-433.	1.3	2
64	C0288: Lack of TAFI Has Deleterious Effect on Experimental Ischemic Stroke: Potential Role of Microparticles. Thrombosis Research, 2014, 133, S5.	0.8	1
65	Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular. ClÃnica E Investigación En Arteriosclerosis, 2019, 31, 152-159.	0.4	1
66	Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation. Biomedicines, 2022, 10, 1557.	1.4	1
67	W03-O-003 Effect of folic acid and vitamin B12 on endothelial function, oxidative stress and prothrombotic factors after renal transplantation. Atherosclerosis Supplements, 2005, 6, 12.	1.2	0
68	W12-P-042 C-reactive protein mediates MMP-1 and MMP-10 expression in human endothelial cells and in patients with atherosclerosis. Atherosclerosis Supplements, 2005, 6, 72.	1.2	0
69	Th-W56:5 MMP-10 (stromelysin-2): New biomarker for clinical and subclinical atherosclerosis. Atherosclerosis Supplements, 2006, 7, 480.	1.2	0
70	PO9-266 VASCULAR MATRIX METALLOPROTEINASE 10 (MMP-10) EXPRESSION IS ASSOCIATED WITH INFLAMMATION AND ATHEROSCLEROSIS DEVELOPMENT IN A MURINE MODEL. Atherosclerosis Supplements, 2007, 8, 83.	1.2	0
71	W43 GENETIC DEFICIENCY IN FUNCTIONAL MMP-10 REDUCES PROGRESSION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-KNOCKOUT MICE. Atherosclerosis Supplements, 2010, 11, 9-10.	1.2	0
72	300 IDENTIFICATION OF MATRIX METALLOPROTEASE 10 (MMP10) AS A KEY NEW MEDIATOR OF THE REGENERATIVE RESPONSE OF THE LIVER. Journal of Hepatology, 2013, 58, S126.	1.8	0

#	Article	IF	CITATIONS
73	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	1.8	ο